Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers.
Eric H BernickerYan XiaoAnup AbrahamBaiyu YangDenise A CroixStella RedpathJulia Engstrom-MelnykRoma ShahJaya MadalaTimothy C AllenPublished in: The oncologist (2021)
Advancement in treatment of lung cancer is accompanied by an increasing number of tests that should be run to determine potential therapy options for each patient. This study assessed adoption of testing recommendations for anaplastic lymphoma kinase rearrangements in a national database. Although test use increased over the time period studied (2012-2019), there is still room for improvement. Efforts are needed to increase test use in undertested groups, thus enabling eligible patients to benefit from novel lung cancer therapies.
Keyphrases
- advanced non small cell lung cancer
- end stage renal disease
- quality improvement
- epidermal growth factor receptor
- healthcare
- chronic kidney disease
- clinical practice
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- tyrosine kinase
- papillary thyroid
- squamous cell carcinoma
- emergency department
- metabolic syndrome
- bone marrow
- electronic health record
- young adults
- mesenchymal stem cells
- patient reported
- human health
- adverse drug
- glycemic control
- protein kinase